Sökning: "new drug development"

Visar resultat 1 - 5 av 143 uppsatser innehållade orden new drug development.

  1. 1. Quantification of Pharmaceuticals at the sub-cellular level using the NanoSIMS

    Uppsats för yrkesexamina på avancerad nivå, Uppsala universitet/Analytisk kemi

    Författare :Maryam Dost; [2024]
    Nyckelord :Mass spectroscopy imaging; AstraZeneca; Nanosims; Therapeutics; pharmacokinetics; pharmacodynamics; Quantitative Visualization; calibration curve; RSF; pharmacology; Data Analysis; Chemistry; Quantification; isotopes; Pharmaceuticals; subcellular; drug; drug target; nucleotide; biodistribution; Bioanalytical electrochemistry; spectroscopy; mass spectrometry; analytical separations; Analytical Chemistry; ROI; Bioanalytical Chemistry; Masspektroskopi avbildning; AstraZeneca; Nanosims; Terapeutik; farmakokinetik; farmakodynamik; Kvantitativ visualisering; kalibreringskurva; RSF; farmakologi; Dataanalys; Kemi; Kvantifiering; isotoper; Läkemedel; subcellulär; läkemedel; läkemedelsmål; bioskopisk elektrofördelning; nukleotid; bioskopisk bioskopisk distribution; masspektrometri; analytiska separationer; analytisk kemi; bioanalytisk kemi;

    Sammanfattning : Mass spectroscopy imaging (MSI) has become a vital tool in modern research due to its ability to visualize the spatial distribution of molecules within tissue samples. The collaboration between researchers at AZ, the University of Gothenburg, and Chalmers University of Technology using the NanoSIMS instrument and MSI-SIMS technology has opened up new avenues of exploration in pharmaceutical development, particularly in examining drugs and metabolites at sub-cellular levels. LÄS MER

  3. 2. Combining Cell Painting, Gene Expression and Structure-Activity Data for Mechanism of Action Prediction

    Master-uppsats, Uppsala universitet/Nationellt resurscentrum för biologi och bioteknik

    Författare :Erik Everett Palm; [2023]
    Nyckelord :bioinformatics; deep learning; machine learning; joint model; tabular data; image data;

    Sammanfattning : The rapid progress in high-throughput omics methods and high-resolution morphological profiling, coupled with the significant advances in machine learning (ML) and deep learning (DL), has opened new avenues for tackling the notoriously difficult problem of predicting the Mechanism of Action (MoA) for a drug of clinical interest. Understanding a drug's MoA can enrich our knowledge of its biological activity, shed light on potential side effects, and serve as a predictor of clinical success. LÄS MER

  4. 3. Vilka läkemedelsframsteg har förbättrat prognosen för HER2-positiv metastaserad bröstcancer? : En litteraturstudie

    Kandidat-uppsats, Linnéuniversitetet/Institutionen för kemi och biomedicin (KOB)

    Författare :Helena Hansson; [2023]
    Nyckelord :HER2; Bröstcancer; Läkemedel;

    Sammanfattning : Breast cancer is one of the deadliest forms of cancers in the world. About 15–30% of all breast cancers are HER2-positive, which involves overexpression of HER2-receptors on the surface of tumor cells. LÄS MER

  5. 4. Advancements of 3D Bioprinting : A market development study

    Master-uppsats, Uppsala universitet/Institutionen för samhällsbyggnad och industriell teknik

    Författare :Alexander Brandt; [2023]
    Nyckelord :3D bioprinting; Market; market developmet; Technology readiness levels;

    Sammanfattning : In most cases new technology emergence does not guarantee overnight success nor is it developed overnight, rather it is a result of industry expertise spanning over several fields of research. 3D bioprinting is an industry that promises revolutionary implications for healthcare and scholars are discussing application areas such as tissue for oncology research, tissue for patient specific drug development and lastly complex organs for implantation. LÄS MER

  7. 5. Paying the Piper : The Consequences of Including Generic Prices in Reimbursement Decisions for Prescription Pharmaceuticals

    Magister-uppsats, Linköpings universitet/Nationalekonomi; Linköpings universitet/Filosofiska fakulteten

    Författare :Anton Klockhoff; Wilmer Larsson; [2023]
    Nyckelord :pharmaceutical reimbursement; genericization; endogenous pricing; treatment displacement; cost-effectiveness analysis; R D incentives;

    Sammanfattning : Objectives: The Dental and Pharmaceutical Benefits Agency (TLV) is responsible for deciding which prescription pharmaceuticals should be subsidized in Sweden. Cost-effectiveness analyses are fundamental to its decision-making, but future price reductions following patent expiry are excluded from these analyses. LÄS MER